^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG CLASS:

    Folate receptor 1-targeted antibody-drug conjugate

    Related drugs:
    8d
    Results of the First Folate Receptor Alpha Testing Trial by the German Quality Assurance Initiative in Pathology (QuIP®). (PubMed, Cancers (Basel))
    Mirvetuximab soravtansine-gynx, an FRα-targeting ADC, has been approved by the FDA and EMA for the treatment of FRα-positive, platinum-resistant ovarian cancer... These findings highlight the critical importance of standardized, validated assays for FRα detection to ensure accurate patient selection for targeted therapies. The study emphasizes the need for further optimization of alternative antibodies before clinical implementation.
    Journal
    |
    FOLR1 ( Folate receptor alpha )
    |
    FOLR1 overexpression
    |
    VENTANA FOLR1 RxDx Assay
    |
    Elahere (mirvetuximab soravtansine-gynx)
    9d
    A Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of GenSci140 in Participants With Advanced Solid Tumors (clinicaltrials.gov)
    P1, N=170, Not yet recruiting, Changchun GeneScience Pharmaceutical Co., Ltd.
    New P1 trial
    23d
    FRAmework-01: A Two-Part Phase 3 Study of LY4170156 in Participants With Platinum-Resistant (Part A) and Platinum-Sensitive (Part B) Ovarian Cancer (clinicaltrials.gov)
    P3, N=1080, Recruiting, Eli Lilly and Company | Not yet recruiting --> Recruiting
    Enrollment open • Platinum sensitive • Platinum resistant
    |
    Avastin (bevacizumab) • carboplatin • paclitaxel • pegylated liposomal doxorubicin • Elahere (mirvetuximab soravtansine-gynx) • topotecan • LY4170156
    23d
    The efficacy and safety of mirvetuximab soravtansine for the treatment of recurrent ovarian cancer: an update systematic review and meta-analysis. (PubMed, Discov Oncol)
    MIRV demonstrates significant efficacy and an acceptable safety profile in the treatment of recurrent ovarian cancer. Its use in platinum-resistant ovarian cancer with high FRα expression represents a particularly promising Therapeutic approach. Furthermore, the combination of MIRV and bevacizumab shows substantial potential for improving outcomes in patients with platinum-resistant disease.
    Retrospective data • Journal
    |
    FOLR1 ( Folate receptor alpha )
    |
    FOLR1 expression
    |
    Avastin (bevacizumab) • Elahere (mirvetuximab soravtansine-gynx)
    24d
    Heterogeneity and Scoring Reproducibility of Folate Receptor 1 Immunohistochemistry in High-grade Serous Carcinoma. (PubMed, Int J Gynecol Pathol)
    Mirvetuximab soravtansine (MIRV) is an antibody-drug conjugate approved for the treatment of adult patients with folate receptor 1 (FRα; FOLR1) positive, platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer, who have received one to three prior systemic treatment regimens...Our study highlights several factors contributing to heterogeneity in FOLR1 reporting. Future studies are needed to better understand the impact of FOLR1 heterogeneity on patient response to therapy.
    Journal
    |
    FOLR1 ( Folate receptor alpha )
    |
    FOLR1 positive
    |
    VENTANA FOLR1 RxDx Assay
    |
    Elahere (mirvetuximab soravtansine-gynx)
    29d
    RAINFOL-04: Study to Assess the Efficacy and Safety of Rina-S Plus Standard of Care Compared to Standard of Care for Maintenance Treatment of Participants With Recurrent Platinum-sensitive Ovarian Cancer After Second-line (2L) Platinum-based Doublet Chemotherapy (clinicaltrials.gov)
    P3, N=528, Not yet recruiting, Genmab
    New P3 trial • Platinum sensitive
    |
    Avastin (bevacizumab) • Rina-S (rinatabart sesutecan)
    29d
    LOXO-FRA-24001: A Study of LY4170156 in Participants With Selected Advanced Solid Tumors (clinicaltrials.gov)
    P1, N=495, Recruiting, Eli Lilly and Company | N=360 --> 495
    Enrollment change • First-in-human
    |
    Keytruda (pembrolizumab) • Avastin (bevacizumab) • carboplatin • itraconazole • LY4170156
    1m
    FLORENZA: A Study to Assess Adverse Events and Change in Disease Activity of Multiple Treatment Combinations With Intravenous Mirvetuximab Soravtansine in Adult Participants With Ovarian Cancer (clinicaltrials.gov)
    P2, N=320, Recruiting, AbbVie | Not yet recruiting --> Recruiting
    Enrollment open • Adverse events
    |
    Avastin (bevacizumab) • carboplatin • Elahere (mirvetuximab soravtansine-gynx)
    1m
    A Study to Assess Anti-Tumor Activity of Intravenously (IV) Infused Carboplatin With Mirvetuximab Soravtansine in Participants With Newly Diagnosed Folate Receptor Alpha (FRα)Expressing Advanced-Stage Serous Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer. (clinicaltrials.gov)
    P2, N=140, Not yet recruiting, AbbVie | Trial completion date: Oct 2029 --> Feb 2030 | Initiation date: Aug 2025 --> Nov 2025
    Trial completion date • Trial initiation date
    |
    Avastin (bevacizumab) • carboplatin • Elahere (mirvetuximab soravtansine-gynx)
    1m
    An Evaluation of Maintenance Therapy Combination Mirvetuximab Soravtansine and Olaparib (clinicaltrials.gov)
    P2, N=53, Recruiting, University of Colorado, Denver | Trial completion date: Dec 2027 --> Oct 2028 | Trial primary completion date: Apr 2026 --> Jan 2028
    Trial completion date • Trial primary completion date • Platinum sensitive
    |
    BRCA (Breast cancer early onset)
    |
    BRCA mutation
    |
    Lynparza (olaparib) • Elahere (mirvetuximab soravtansine-gynx)
    1m
    Single-Cell Transcriptomics Reveals a Multi-Compartmental Cellular Cascade Underlying Elahere-Induced Ocular Toxicity in Rats. (PubMed, Pharmaceuticals (Basel))
    Elahere induces complex, multi-compartmental ocular toxicity characterized by initial perturbations in vascular endothelial and immune cell populations followed by the arrest of epithelial differentiation and stromal remodeling. These findings reveal a cascade of cellular disruptions and provide mechanistic insights into mitigating Elahere-associated ocular side effects.
    Preclinical • Journal
    |
    FOLR1 ( Folate receptor alpha )
    |
    Elahere (mirvetuximab soravtansine-gynx)
    1m
    RAINFOL-02: Study to Assess the Efficacy of Rina-S Compared to Treatment of Investigator's Choice in Participants With Platinum Resistant Ovarian Cancer (clinicaltrials.gov)
    P3, N=530, Recruiting, Genmab | Trial primary completion date: May 2027 --> Feb 2027
    Trial primary completion date • Platinum resistant
    |
    gemcitabine • paclitaxel • pegylated liposomal doxorubicin • topotecan • Rina-S (rinatabart sesutecan)